CN107213454A - Composition and regenerating bone or cartilage method for cartilage regeneration in situ - Google Patents
Composition and regenerating bone or cartilage method for cartilage regeneration in situ Download PDFInfo
- Publication number
- CN107213454A CN107213454A CN201710333190.2A CN201710333190A CN107213454A CN 107213454 A CN107213454 A CN 107213454A CN 201710333190 A CN201710333190 A CN 201710333190A CN 107213454 A CN107213454 A CN 107213454A
- Authority
- CN
- China
- Prior art keywords
- cartilage
- cell
- situ
- parts
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a kind of composition for cartilage regeneration in situ, the composition includes the albumen medicine for including 1 mM/l of 1 micromoles per liter in buffer solution, the buffer solution.The composition for cartilage regeneration in situ of the present invention, activates or induce progenitor cells or the stem cell of cartilage cell in articular cavity with the mode of albumen medicine, makes its breeding or/and differentiating cartilage-forming cell, causes regenerating bone or cartilage, reparation cartilage damage；That is, using the cell of human body itself, being induced with albumen medicine, the new cartilage cell of generation and tissue, to repair cartilage damage comprehensively；The system expressing quantity is high, and controllability is strong, and production cost is relatively low, and with good biological activity, easily realizes large-scale production.
Description
Technical field
The present invention relates to genetically engineered drug field, more particularly to a kind of composition and cartilage for cartilage regeneration in situ
Renovation process.
Background technology
Osteoarthritis is also known as degenerative arthritis, is arthritic most common form, is also to cause the of deformity in the world
Four first causes.It influences more than 70% the elderly between 55 years old to 70 years old.It is aged because Chinese population radix is big
Change seriously, osteoarthritis occurs more universal.It is estimated that the Human Osteoarthritis of China is more than 65,000,000 people.Osteoarthritis
Be mainly characterized by the gradually decomposition of articular cartilage, and ultimately result in the functional fault in synovial membrane joint.In Osteoarthritis,
Cartilage surface fault rupture and abrasion so that direct friction between subchondral bone, cause pain, and swelling hinders the motion in joint.
Over time, joint may be deformed.In addition, at bone bone junction, the projection of meeting long bone, referred to as spur or spur.
Small pieces bone tissue or cartilaginous tissue can come off and be floated in articular cavity, cause more pains and injury.Cartilage is due to lacking
Weary neural domination and the supply of blood vessel, its own power of regeneration are very poor, and how effectively repairing articular cartilage is always clinic
On a great problem.In Osteoarthritis, there is breakage cartilaginous tissue many places, and cause inflammation.Pain and moving difficulty are to suffer from
The greatest problem of person.
There is no effective treatment means to osteoarthritis in the world at present, existing primary treatments include pain management
And physical treatment, but just for symptom, it is impossible to change the process of disease.The osteoarthritis of most of patient can deteriorate with the time,
Total joint replacement can only finally be sought help from.
The content of the invention
Technical problem solved by the invention is to provide a kind of regenerating bone or cartilage that is used for, reparation cartilage damage cartilage original position
The composition and regenerating bone or cartilage method of regeneration.
In order to solve the above technical problems, the invention provides a kind of composition for cartilage regeneration in situ, the combination
Thing includes the albumen medicine for including -1 mM/l of 1 micromoles per liter in buffer solution, the buffer solution.
Further, the albumen medicine is SOX9 albumen medicines.
Further, the buffer solution also includes sucrose, arginine, sodium chloride, potassium chloride, glycerine.
Further, the sucrose, arginine, sodium chloride, potassium chloride, the amount of the material of glycerine are respectively 1-5 parts, 2-
3 parts, 1-10 parts, 0.2-1 parts, 2-10 parts.
Further, the sucrose, arginine, sodium chloride, potassium chloride, the summation of the amount of the material of glycerine are not less than 10
Micromole.
A kind of cartilage regeneration in situ method, it is used to make in articular cavity or neighbouring cartilage cell's in-situ regeneration, described
Intraarticular injection buffer solution, the buffer solution includes the albumen medicine of -1 mM/l of 1 micromoles per liter, so that the albumen medicine
Into in the progenitor cells, precursory cell or stem cell of the cartilage cell, and the albumen medicine is set to enter the cartilage cell's
In progenitor cells, precursory cell or the nucleus of stem cell.
Further, the albumen medicine is that can enter the SOX9 albumen medicines of cell.
Further, the buffer solution also includes sucrose, arginine, sodium chloride, potassium chloride, glycerine.
Further, the sucrose, arginine, sodium chloride, potassium chloride, the amount of the material of glycerine are respectively 1-5 parts, 2-
3 parts, 1-10 parts, 0.2-1 parts, 2-10 parts.
Further, the sucrose, arginine, sodium chloride, potassium chloride, the summation of the amount of the material of glycerine are not less than 10
MM.
The present invention activates or induced progenitor cells or the stem cell of the cartilage cell in articular cavity with the mode of albumen medicine, makes it
Breeding or/and differentiating cartilage-forming cell, cause regenerating bone or cartilage, repair cartilage damage；That is, utilizing the thin of human body itself
Born of the same parents, are induced with albumen medicine, the new cartilage cell of generation and tissue, to repair cartilage damage comprehensively；The system protein expression
Amount is high, and controllability is strong, and production cost is relatively low, and with good biological activity, easily realizes large-scale production.
Embodiment
It is described below in detail in embodiments of the present invention, the embodiment and shows, wherein identical from beginning to end or class
As label represent same or similar element or the element with same or like function.Following embodiments are intended to be used to explain
The present invention, and be not considered as limiting the invention.
The present embodiment provides a kind of composition for cartilage regeneration in situ, and the composition includes buffer solution, described slow
The albumen medicine of -1 mM/l of 1 micromoles per liter is included in fliud flushing.The composition for cartilage regeneration in situ of the present invention, uses egg
The mode of baiyao activates or induced progenitor cells or the stem cell of the cartilage cell in articular cavity, it is bred or/and is divided into soft
Osteocyte, causes regenerating bone or cartilage, repairs cartilage damage；That is, using the cell of human body itself, being lured with albumen medicine
Lead, the new cartilage cell of generation and tissue, to repair cartilage damage comprehensively；The system expressing quantity is high, and controllability is strong, production
Advantage of lower cost, and with good biological activity, easily realize large-scale production.
, can be first in the left Injection in knuckle articular cavity sodium glutamate iodoacetic acid of rat by taking the knee of rat as an example in experiment
(Monosodium iodoacetate, MIA), destroys cartilage, and inducing osteoarthritis is scorching；Then, after waiting 8 days, on a left side for rat
The buffer solution of Injection in knuckle articular cavity medicine containing albumen, left kneed pain is measured by measuring left and right back leg weight bearing difference
Degree, it is found that after the buffer solution of injection medicine containing albumen, after 50 days, cartilage gradually regenerates, the left knee joint of left knee of rat
Pain degree tend towards stability, than starting, pain index is reduced to 0.21 from 0.35, effect than antalgesic Celebrex (50
Pain index will be for 0.28) will good several times after it.
Preferably, the use of albumen medicine can enter the SOX9 albumen medicines of cell.For example, the amino of the SOX9 albumen for people
Acid sequence is as follows：
Mnlldpfmkmtdeqekglsgapsptmsedsagspcpsgsgsdtentrpqentfpkgepdlkkeseedkfpvcireav
sqvlkgydwtlvpmpvrvngssknkphvkrpmnafmvwaqaarrkladqyphlhnaelsktlgklwrllnesekrpf
veeaerlrvqhkkdhpdykyqprrrksvkngqaeaeeateqthispnaifkalqadsphsssgmsevhspgehsgqs
qgpptppttpktdvqpgkadlkregrplpeggrqppidfrdvdigelssdvisnietfdvnefdqylppnghpgvpa
thgqvtytgsygisstaatpasaghvwmskqqapppppqqppqappapqappqpqaappqqpaappqqpqahtlttl
ssepgqsqrthikteqlspshyseqqqhspqqiayspfnlphyspsyppitrsqydytdhqnsssyyshaagqgtgl
ystftymnpaqrpmytpiadtsgvpsipqthspqhweqpvytqltrp
Buffer solution also includes sucrose, arginine, sodium chloride, potassium chloride, glycerine；Sucrose, arginine, sodium chloride, potassium chloride,
The amount of the material of glycerine is respectively 1-5 parts, 2-3 parts, 1-10 parts, 0.2-1 parts, 2-10 parts.Preferably, sucrose, arginine, chlorine
Change sodium, potassium chloride, the summation of the amount of the material of glycerine and be not less than 10 micromoles.
The present embodiment additionally provides a kind of cartilage regeneration in situ method, and it is used to make in articular cavity or neighbouring cartilage cell
In-situ regeneration, in intraarticular injection buffer solution, buffer solution includes the albumen medicine of -1 mM/l of 1 micromoles per liter, so that egg
Baiyao enters in progenitor cells, precursory cell or the stem cell of the cartilage cell, and albumen medicine is entered the cartilage cell's
In progenitor cells, precursory cell or the nucleus of stem cell.This method is a kind of by the intraarticular injection of sickness influence in patient
Buffer solution, Main Ingredients and Appearance therein is albumen medicine.Albumen medicine can enter the cells of superficial layer of cartilage.These cellss of superficial layer are cartilages
The progenitor cells of cell, the ability with breeding and differentiation.But they are in most cases in a dormant state.Into cartilage table
The albumen medicine of confluent monolayer cells can activate them, make its breeding, differentiating cartilage-forming cell.Newly-generated cartilage cell further forms new
Cartilage.The reparation of cartilage makes it possible healing osteoarthritis.
Albumen medicine is modified or the SOX9 albumen medicines without modification.Buffer solution also include sucrose, arginine, sodium chloride,
Potassium chloride, glycerine.Further, the sucrose, arginine, sodium chloride, potassium chloride, the amount of the material of glycerine are respectively 1-5
Part, 2-3 parts, 1-10 parts, 0.2-1 parts, 2-10 parts.Further, the sucrose, arginine, sodium chloride, potassium chloride, glycerine
Material amount summation be not less than 10 micromoles.
Cartilage and treatment osteoarthritis are repaired in this case with the mode of intraarticular injection albumen medicine.The effect machine of the albumen medicine
Reason is to activate progenitor cells, precursory cell or the stem cell of cartilage cell；The albumen medicine can enter this kind of intracellular work.The egg
The nucleus that baiyao can enter cell works.This method is applicable not only to people, is also applied for other animals such as horse, dog.The egg
Baiyao effect cell in articular cavity or near.This method can treat cartilage damage, osteoarthritis, small joints in lumbar spine bone
The diseases relevant with cartilage such as property arthritis.
It is described above, only it is highly preferred embodiment of the present invention, any formal limitation not is made to the present invention, appoints
What those skilled in the art, without departing from the scope of the technical proposal of the invention, using in the method for the disclosure above
Appearance makes many possible variations and modification to technical solution of the present invention, belongs to protective scope of the claims.
Claims (10)
1. a kind of composition for cartilage regeneration in situ, it is characterised in that the composition includes buffer solution, the buffer solution
In include the albumen medicine of -1 mM/l of 1 micromoles per liter.
2. it is used for the composition of cartilage regeneration in situ as claimed in claim 1, it is characterised in that：The albumen medicine is to enter
The SOX9 albumen medicines of cell.
3. it is used for the composition of cartilage regeneration in situ as claimed in claim 2, it is characterised in that：The buffer solution also includes sugarcane
Sugar, arginine, sodium chloride, potassium chloride, glycerine.
4. it is used for the composition of cartilage regeneration in situ as claimed in claim 3, it is characterised in that：The sucrose, arginine, chlorine
It is respectively 1-5 parts, 2-3 parts, 1-10 parts, 0.2-1 parts, 2-10 parts to change sodium, potassium chloride, the amount of the material of glycerine.
5. it is used for the composition of cartilage regeneration in situ as claimed in claim 4, it is characterised in that：The sucrose, arginine, chlorine
Change sodium, potassium chloride, the summation of the amount of the material of glycerine and be not less than 10 micromoles.
6. a kind of cartilage regeneration in situ method, it is used to make in articular cavity or neighbouring cartilage cell's in-situ regeneration, and its feature exists
In：In the intraarticular injection buffer solution, the buffer solution includes the albumen that concentration is -1 mM/l of 1 micromoles per liter
Medicine, so that the albumen medicine enters in progenitor cells, precursory cell or the stem cell of the cartilage cell, and enters the albumen medicine
Enter in the nucleus of progenitor cells, precursory cell or stem cell of the cartilage cell.
7. cartilage regeneration in situ method as claimed in claim 6, it is characterised in that：The albumen medicine is SOX9 albumen medicines.
8. cartilage regeneration in situ method as claimed in claim 7, it is characterised in that：The buffer solution also includes sucrose, smart ammonia
Acid, sodium chloride, potassium chloride, glycerine.
9. cartilage regeneration in situ method as claimed in claim 8, it is characterised in that：The sucrose, arginine, sodium chloride, chlorine
It is respectively 1-5 parts, 2-3 parts, 1-10 parts, 0.2-1 parts, 2-10 parts to change potassium, the amount of the material of glycerine.
10. cartilage regeneration in situ method as claimed in claim 9, it is characterised in that：The sucrose, arginine, sodium chloride, chlorine
Change potassium, the summation of the amount of the material of glycerine is not less than 10 micromoles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710333190.2A CN107213454A (en) | 2017-05-12 | 2017-05-12 | Composition and regenerating bone or cartilage method for cartilage regeneration in situ |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710333190.2A CN107213454A (en) | 2017-05-12 | 2017-05-12 | Composition and regenerating bone or cartilage method for cartilage regeneration in situ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107213454A true CN107213454A (en) | 2017-09-29 |
Family
ID=59944196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710333190.2A Pending CN107213454A (en) | 2017-05-12 | 2017-05-12 | Composition and regenerating bone or cartilage method for cartilage regeneration in situ |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107213454A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109731095A (en) * | 2019-03-14 | 2019-05-10 | 广东龙帆生物科技有限公司 | It is a kind of for preventing or treating hepatitis b virus infected drug and preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1498266A (en) * | 2001-01-30 | 2004-05-19 | Compositions and methods for treatment and repair of defects or lesion in articular cartilage using synovial-derivated tissue or cells | |
| KR20130112427A (en) * | 2012-04-04 | 2013-10-14 | 동국대학교 산학협력단 | Parmaceutical composition comprising stem cell transduced sox-trio gene and fibrin gel for enhancing chondrogenesis |
| WO2015188020A1 (en) * | 2014-06-06 | 2015-12-10 | Vivoscript, Inc. | Methods for repairing cartilage damage |
-
2017
- 2017-05-12 CN CN201710333190.2A patent/CN107213454A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1498266A (en) * | 2001-01-30 | 2004-05-19 | Compositions and methods for treatment and repair of defects or lesion in articular cartilage using synovial-derivated tissue or cells | |
| KR20130112427A (en) * | 2012-04-04 | 2013-10-14 | 동국대학교 산학협력단 | Parmaceutical composition comprising stem cell transduced sox-trio gene and fibrin gel for enhancing chondrogenesis |
| WO2015188020A1 (en) * | 2014-06-06 | 2015-12-10 | Vivoscript, Inc. | Methods for repairing cartilage damage |
Non-Patent Citations (5)
| Title |
|---|
| HANNELE UUSITALO等: "Accelerated Up-Regulation of L-Sox5, Sox6, and Sox9 by BMP-2 Gene Transfer During Murine Fracture Healing", 《JOURNAL OF BONE AND MINERAL RESEARCH》 * |
| 余元勋等: "《中国分子骨质疏松学》", 30 April 2016, 安徽科学技术出版社 * |
| 储沨婷等: "Sox9蛋白在软骨成骨中的作用", 《国外医学口腔医学分册》 * |
| 尤罗•朗格尔（瑞典）: "《细胞穿透肽 研究方法与实验指南》", 30 September 2016, 世界图书出版西安有限公司 * |
| 邹军等: "《中医学基础》", 31 October 2013, 复旦大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109731095A (en) * | 2019-03-14 | 2019-05-10 | 广东龙帆生物科技有限公司 | It is a kind of for preventing or treating hepatitis b virus infected drug and preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nimni | Collagen | |
| Shah et al. | Outcome of allogeneic adult stem cell therapy in dogs suffering from osteoarthritis and other joint defects | |
| CN101810855B (en) | II-type collagen joint cartilage fluid and preparation method thereof | |
| Hanson et al. | Oral treatment with a glucosamine-chondroitin sulfate compound for degenerative joint disease in horses: 25 cases | |
| Ghosh et al. | The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep I. Gait analysis and radiological and morphological studies | |
| Lietman et al. | Stimulation of proteoglycan synthesis in explants of porcine articular cartilage by recombinant osteogenic protein-1 (bone morphogenetic protein-7) | |
| Cole et al. | Human physiology, biochemistry and basic medicine | |
| CN102630157B (en) | Injectable compositions for intra-articular use combining a viscosupplementation agent and a fibroblast growth medium | |
| Nowlan et al. | Immobilized chicks as a model system for early‐onset developmental dysplasia of the hip | |
| KR20050044415A (en) | Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis | |
| US20120177619A1 (en) | Composition comprising a haematic component and its use for the treatment of degenerative joint disease | |
| CN103987402A (en) | Use of growth hormone fragments | |
| Van Nguyen et al. | Pulsed electromagnetic fields for treating osteo-arthritis | |
| WO2013136871A1 (en) | Oversulfated chondroitin composition | |
| CN107213454A (en) | Composition and regenerating bone or cartilage method for cartilage regeneration in situ | |
| BR112016018704B1 (en) | process for the production of a transplantable cartilage material for tissue engineering | |
| Succar et al. | Priming Adipose‐Derived Mesenchymal Stem Cells with Hyaluronan Alters Growth Kinetics and Increases Attachment to Articular Cartilage | |
| EROĞLU et al. | Platelet-rich plasma vs prolotherapy in the management of knee osteoarthritis: randomized placebo-controlled trial | |
| Qi et al. | Radial extracorporeal shock wave therapy promotes osteochondral regeneration of knee joints in rabbits | |
| Kim et al. | Intra-articular injections of allogeneic mesenchymal stromal cells vs. high molecular weight hyaluronic acid in dogs with osteoarthritis: exploratory data from a double-blind, randomized, prospective clinical trial | |
| Bayat et al. | Effect of low-power helium-neon laser irradiation on 13-week immobilized articular cartilage of rabbits | |
| Shpansky et al. | A traumatic case in Mammuthus trogontherii chosaricus Dubrovo (1966) | |
| ES2207550T3 (en) | COMPOSITION THAT INCLUDES AN EXTRACT OF PERN CANALICULUS, METILSULFONYLMETHANE AND GLUCOSAMINE, AND USE OF THE SAME. | |
| Sharifi et al. | Injury in Achilles' Tendon in Dog | |
| Leite et al. | ICRS virtual convention 2021: Orthoregenerative therapy from basic science to clinical application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170929 |
|
| RJ01 | Rejection of invention patent application after publication |